Segments (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:

	Three Months Ended   June 30,				Six Months Ended   June 30,
	2023		2022		2023		2022
Biopharmaceuticals	$	(17,880)	$	(19,997)	$	(39,277)	$	(40,874)
Exemplar	(83)		795		38		4,353
Segment Adjusted EBITDA for reportable segments	$	(17,963)	$	(19,202)	$	(39,239)	$	(36,521)

Revenues by reportable segment were as follows:

	Three Months Ended June 30, 2023
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	—	$	1,767	$	1,767
Intersegment revenues	—		—		—
Total segment revenues	$	—	$	1,767	$	1,767

	Three Months Ended June 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	70	$	2,841	$	2,911
Intersegment revenues	—		—		—
Total segment revenues	$	70	$	2,841	$	2,911

	Six Months Ended June 30, 2023
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	—	$	3,618	$	3,618
Intersegment revenues	—		—		—
Total segment revenues	$	—	$	3,618	$	3,618

	Six Months Ended June 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	154	$	8,270	$	8,424
Intersegment revenues	—		—		—
Total segment revenues	$	154	$	8,270	$	8,424

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

	Three Months Ended   June 30,				Six Months Ended   June 30,
	2023		2022		2023		2022
Segment Adjusted EBITDA for reportable segments	$	(17,963)	$	(19,202)	$	(39,239)	$	(36,521)
All Other Segment Adjusted EBITDA	—		—		—		—
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	101		172		255		668
Interest Income	828		37		1,461		75
Other expenses:
Interest expense	(136)		(2,063)		(460)		(4,101)
Depreciation and amortization	(1,693)		(1,835)		(3,404)		(3,753)
Gain (loss) on disposals of assets	40		—		40		—
Impairment losses	—		(638)		—		(1,120)
Stock-based compensation expense	(2,188)		(2,279)		(5,320)		(5,803)
Adjustment related to accrued bonuses paid in equity awards	—		—		3,361		1,698
Equity in net loss of affiliates	—		—		—		(1)
Other	—		(105)		—		(105)
Shares issue for payment of services	—		—		(545)		(576)
Corporate noncash items	627		(203)		678		(468)
Eliminations	—		(32)		—		(97)
Consolidated net loss from continuing operations before income taxes	$	(20,384)	$	(26,148)	$	(43,173)	$	(50,104)

Reconciliation of Revenue from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:

	Three Months Ended   June 30,				Six Months Ended   June 30,
	2023		2022		2023		2022
Total segment revenues from reportable segments	$	1,767	$	2,911	$	3,618	$	8,424
Elimination of intersegment revenues	—		—		—		—
Total consolidated revenues	$	1,767	$	2,911	$	3,618	$	8,424